Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

SpringWorks Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

SpringWorks Therapeutics şirketinin toplam hissedar öz sermayesi $556.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $617.3M ve $60.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$383.89m
Eşitlik	US$556.73m
Toplam yükümlülükler	US$60.60m
Toplam varlıklar	US$617.33m

Son finansal sağlık güncellemeleri

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

May 03

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Sep 20

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Jun 07

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Feb 22

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Nov 09

Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

Jun 06

Recent updates

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Aug 07

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

May 11

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

May 03

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

Apr 25

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

Apr 19

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Sep 20

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Jun 07

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Feb 22

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Nov 09

Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

Dec 30

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Dec 14

SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business

Sep 15

SpringWorks shows durable effect for neurofibroma therapy with long-term data

Jun 15

SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma

Jun 07

We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow

May 31

SpringWorks Therapeutics EPS misses by $0.11

May 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SWTX 'nin kısa vadeli varlıkları ( $431.3M ) kısa vadeli yükümlülüklerini ( $54.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: SWTX şirketinin kısa vadeli varlıkları ( $431.3M ) uzun vadeli yükümlülüklerini ( $6.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SWTX borçsuzdur.

Borcun Azaltılması: SWTX son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: SWTX şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: SWTX tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

SpringWorks Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

Recent updates

CEO & Director notifies of intention to sell stock

Consensus revenue estimates increase by 35%

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Forecast to breakeven in 2026

SpringWorks Therapeutics, Inc. Appoints Dr. Martin Mackay to Its Board of Directors

SpringWorks Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Springworks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with Nf1-Pn

Chief Operating Officer notifies of intention to sell stock

SpringWorks Therapeutics, Inc. Announces Data to Be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

Consensus revenue estimates increase by 54%, EPS downgraded

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

SpringWorks Therapeutics, Inc. to Report Q1, 2024 Results on May 02, 2024

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

SpringWorks Therapeutics, Inc., Annual General Meeting, May 16, 2024

Consensus revenue estimates increase by 21%, EPS downgraded

SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Consensus revenue estimates increase by 33%, EPS downgraded

Price target increased by 7.7% to US$67.53

SpringWorks Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Price target increased by 11% to US$61.86

SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer

Consensus revenue estimates decrease by 13%

SpringWorks Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.999982 million.

New minor risk - Shareholder dilution

SpringWorks Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Consensus revenue estimates decrease by 29%

Price target increased by 15% to US$54.83

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

New minor risk - Share price stability

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

Consensus revenue estimates decrease by 26%

SpringWorks Therapeutics, Inc. Announces Positive Topline Results from the Phase 2B ReNeu Trial of Mirdametinib in NF1-PN

Consensus revenue estimates decrease by 12%

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

SpringWorks Therapeutics, Inc. Appoints Tai-An Lin as Chief Scientific Officer

Consensus revenue estimates fall by 81%

Price target decreased by 9.8% to US$50.50

SpringWorks Therapeutics, Inc.(NasdaqGS:SWTX) dropped from Russell Small Cap Comp Value Index

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

SpringWorks Therapeutics, Inc. Announces PDUFA Date Extension for Nirogacestat NDA

Insufficient new directors

Consensus revenue estimates increase by 125%

Springworks Therapeutics, Inc. Announces Data from Two Collaboration-Sponsored Clinical Studies Evaluating Nirogacestat in Combination with B-Cell Maturation Agent in Patients with Relapsed or Refractory Multiple Myeloma

Consensus revenue estimates decrease by 85%

Price target decreased by 12% to US$57.00

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Springworks Therapeutics Completes Submission of New Drug Application to the Fda for Nirogacestat for the Treatment of Adults with Desmoid Tumors

Price target decreased to US$64.50

Price target decreased to US$69.80

Price target decreased to US$69.80

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Springworks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

SpringWorks Therapeutics, Inc. Announces Resignation of Michael Burgess as the Head of Research and Development

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022

SpringWorks Therapeutics, Inc. announced that it expects to receive $224.349775 million in funding from EcoR1 Capital, LLC, Boxer Capital LLC, The Invus Group, LLC, Deerfield Management Company, L.P. Series C, Perceptive Advisors LLC and other investor

SpringWorks drops 21% as Allogene drops lead asset in combination study

SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15

Sizing Up SpringWorks Therapeutics

SpringWorks Therapeutics, Inc. Announces Resignation of Stephen Squinto as Member of the Board

Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

Price target decreased to US$95.40

SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases

SpringWorks Therapeutics, Inc., Annual General Meeting, May 19, 2022

Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Springworks Therapeutics Announces Clinical Collaboration with Abbvie to Evaluate Nirogacestat in Combination with Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma

Springworks Therapeutics, Inc. Announces Dosing of First Patient in Phase 1B/2 Trial Evaluating Nirogacestat in Combination with Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma